Corcept Therapeutics Reaffirms 2026 Revenue Guidance Amid Relacorilant FDA Decision Anticipation
Corcept Therapeutics (CORT) reported third-quarter 2026 revenue of $340.5 million, maintaining its full-year revenue guidance of $1.1 billion to $1.2 billion. The company's financial outlook remains steady as it prepares for a significant regulatory milestone regarding its drug candidate, relacorilant. Management has set long-term commercial targets for Cushing’s syndrome, projecting potential revenues between $3 billion and $5 billion by 2030. Investors are closely watching the upcoming FDA decision scheduled for December 17, which will serve as a critical catalyst for the company's future growth trajectory.
Tickers: $CORT